News & Events

September 16, 2025

Apollo Therapeutics’ Anti-IL-18 Antibody Camoteskimab Met the Primary Endpoint in a Double-Blind, Randomized, Placebo-Controlled Phase 2a Clinical Trial in Atopic Dermatitis

May 05, 2025

Apollo Therapeutics marks World Pulmonary Hypertension Day with update on the clinical development of APL-9796 (anti-ZIP12 mAb) for the treatment of Pulmonary Hypertension

January 08, 2025

Apollo appoints new Special Advisor, Dr Husseini Manji

November 12, 2024

Apollo Therapeutics Signs Exclusive Ex-China License From Sunshine Lake Pharma for Clinical-Stage FGF21 / GLP-1 Dual Receptor Agonist, a Therapeutic With Major Commercial Potential in Multiple Indications

October 16, 2024

Apollo appoint Dr Dipender Gill to the strategic advisory board

July 22, 2024

Apollo Therapeutics and the University of Oxford enter into drug discovery and development collaboration

Apollo Therapeutics will inject capital and expertise into pipeline of potentially lifesaving medici

January 02, 2024

Apollo Therapeutics Announces Second Close Of Series C Financing Bringing Total Raised In Round To $260 Million

September 06, 2023

Apollo Therapeutics Closes $226.5 Million Series C Financing Led by Patient Square Capital

November 14, 2022

Apollo Therapeutics and The Institute of Cancer Research enter into collaboration for cancer drug development

ICR joins University of Cambridge, Imperial College London, UCL and King’s College London as a str